08:13 AM EDT, 06/03/2024 (MT Newswires) -- (Adds Blackstone comment in fourth paragraph.)

Blackstone (BX) is exploring the sale of Japanese consumer healthcare firm Alinamin Pharmaceutical for around 300 billion yen ($1.9 billion), Bloomberg reported Monday, citing people familiar with the situation.

Alinamin is drawing interest from CVC Capital Partners, EQT AB, and MBK Partners, according to the report, citing the people.

Additionally, an IPO remains a viable option, the sources reported.y said.

Blackstone declined to comment, while CVC Capital Partners, EQT AB, and MBK Partners did not immediately respond to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 122.28, Change: +1.78, Percent Change: +1.48